Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 187

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: Biological lessons, current challenges, and clinical perspectives: Hepatology

Open access
Salem, Riad, Mazzaferro, Vincenzo, Sangro, Bruno·2013·Hepatology

Abstract

Hepatocellular carcinoma (HCC) is the sixth-most common malignancy diagnosed worldwide.1 Late-stage presentation, comorbidities, and limited donor availability enables only 10% of patients to receive curative therapies. Hence, there exists a critical need for novel treatments addressing HCC at all stages. During the last decade, several transarterial locoregional therapies have been developed. One of these, yttrium-90 (90Y) radioembolization, has matured into a recognized treatment option, with a demonstration of a clear palliative role by inducing necrosis and delaying progression.2-8 This overview will describe the biological rationale for 90Y, highlight seminal data, propose research questions, and discuss the future role of 90Y in HCC. HCC is a tumor that arises almost exclusively in cirrhosis caused by viruses, alcohol, or non-alcohol-related steatohepatitis, insulin-resistant metabolism, autoimmunity, and others. Therefore, survival of HCC patients is related to the tumor and underlying liver condition. In fact, genomic data coded in nontumoral cirrhotic tissue have shown the ability to determine risk of tumor recurrence after resection or ablation; this explains the tendency of HCC to recur and develop de novo tumor foci usually confined within the liver during the history of the disease.9 The observation that HCC is mostly a liver-limited cancer has allowed the development of a wide range of therapeutic strategies aimed at locoregional approaches and organ replacement by means of transplantation.10 Experience gained in recent years indicates that HCC is truly a radiosensitive tumor. External irradiation (electrons, protons, and carbon) produces significant tumor responses in patients with HCC.11 Limitations to its clinical applicability are determined by the coexisting intense radiosensitivity of normal liver tissue, precluding the irradiation of large liver volumes with doses >35-40 Gy.12 Intra-arterial (IA) radiation therapies were developed in an attempt to capitalize on the arterial perfusion of HCC, with the aim of delivering tumoricidal doses to liver tumors irrespective of number, size, and location (sparing normal parenchyma). Radioembolization is a term proposed by a panel of experts to define those procedures in which radioactive microspheres are injected IA for internal radiation purposes.13 It is the artery in which microspheres are injected that defines the volume of liver tissue exposed to radiation (intravascular brachytherapy). Contrary to transarterial chemoembolization (TACE), in which a combination of drug and ischemia are likely to drive the antitumor effect, 90Y effects are predominantly caused by the radiation effect, with a minor contribution from microembolization.14 Given this mechanism of action, patients with macrovascular invasion may be treated. The commercially available microspheres include resin (SIR-Spheres; SIRTeX Medical, Lane Cove, NSW, Australia) or glass (TheraSphere; Nordion, Ottawa, Ontario, Canada); both are loaded with 90Y, a pure beta emitter (i.e., no isolation or radioprotection). 90Y is a high-energy radiation source with a short half-life (2.67 days) and a short tissue penetration (2.5 mm). Within 2 weeks after injection, >95% of the radiation has been deposited. Glass and resin microspheres differ in several characteristics (specific activity and number of spheres). Despite these differences, clinical outcomes appear equivalent.15 The biological effects of radiotherapy are mediated by the absorbed dose (energy absorbed/unit mass). With 90Y, absorbed dose may be heterogeneous, depending on hemodynamics and variable intratumoral vessel density within each liver tumor.16 Despite this heterogeneity, most injected microspheres are preferentially absorbed into the tumor microvasculature in a 3:1 to 20:1 ratio, compared to the normal liver, with a preferential deposition in the periphery of nodules (dose, >500 Gy).17, 18 Exposure to radiation then produces irreversible cell damage in tumor epithelial, stromal, and endothelial cells (ECs) that ultimately leads to compromised tumor growth. In mouse models, radiation preferentially damages ECs of the gut microvasculature, suggesting that ECs may represent the principal targets for radiation and that the death of epithelial stem cells may be a secondary event in gastrointestinal (GI) toxicity.19 Similarly, it has been proposed that tumor cell death in response to radiotherapy may represent a secondary event after the death of ECs.20 High doses to hyperperfused tissue suggest that vessel damage may be key to the antitumoral effect of 90Y. Heterogeneous deposition of microspheres results in a variability of dosimetric considerations. In radioembolization, millions of 90Y sources are infused into the arterial vasculature. To predict ultimate 90Y deposition, a simulation angiogram is performed 1-2 weeks before treatment using 20-100 micron-sized technetium-99m-labeled macroaggregated albumin (Tc-MAA) particles. Plana

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.26382

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 187

Metadata

Authors
Salem, R., Mazzaferro, V., & Sangro, B.
Venue
Hepatology
Published
2013-10-04
Volume
58
Issue
6
Pages
2188-2197
ISSN
0270-9139 (ISSN-L)
OpenAlex
W2166590925
Cited by
187
References
2
FWCI
12.66
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.